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Abstract
The main objective of the present study was to find suitable DNA-targeting sequences (DTS) for the construction of plasmid 
vectors to be used to treat ischemic diseases. The well-known Simian virus 40 nuclear DTS (SV40-DTS) and hypoxia-responsive 
element (HRE) sequences were used to construct plasmid vectors to express the human vascular endothelial growth factor gene 
(hVEGF). The rate of plasmid nuclear transport and consequent gene expression under normoxia (20% O2) and hypoxia (less 
than 5% O2) were determined. Plasmids containing the SV40-DTS or HRE sequences were constructed and used to transfect 
the A293T cell line (a human embryonic kidney cell line) in vitro and mouse skeletal muscle cells in vivo. Plasmid transport to 
the nucleus was monitored by real-time PCR, and the expression level of the hVEGF gene was measured by ELISA. The in 
vitro nuclear transport efficiency of the SV40-DTS plasmid was about 50% lower under hypoxia, while the HRE plasmid was 
about 50% higher under hypoxia. Quantitation of reporter gene expression in vitro and in vivo, under hypoxia and normoxia, 
confirmed that the SV40-DTS plasmid functioned better under normoxia, while the HRE plasmid was superior under hypoxia. 
These results indicate that the efficiency of gene expression by plasmids containing DNA binding sequences is affected by the 
concentration of oxygen in the medium.
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Recent biotechnological advances have allowed the 
development of new technologies for the delivery of ex-
ogenous genetic material to mammalian cells. Functional 
genetic studies of these new technologies have resulted 
in a new therapeutic modality termed gene therapy. Of the 
several types of vectors available for gene therapy, naked 
DNA is used in 20% of current clinical trials (http://www.wiley.
co.uk/genetherapy/clinical/). This non-viral vector is easy to 
produce, handle, and purify and generates a low immune 
response, allowing repeated administrations if necessary. 
Its utility in gene therapy, however, is currently limited by 
its low rate of transfection. Gene expression levels can be 
increased by facilitating plasmid entry into the nucleus (1), 
since the main barrier for plasmid vector transfection is the 
nuclear envelope crossing (2-5).
In 1997, Dean (1) demonstrated that plasmid nuclear 
import could be facilitated by the insertion into the plasmid 
of nuclear DNA-targeting sequences (DTS), which are 
transcription factor binding sites. The modified plasmid DNA 
is actively transported through nuclear membrane pores of 
non-dividing cells. In a subsequent study, this group isolated 
a 72-bp sequence from the Simian virus 40 (SV40) promoter 
containing binding sites for the NF-kappaB, Oct-1, SP1, SP2, 
AP1, and AP2 transcription factors (4,6). The transcription 
factors are transported into the nucleus by importins and 
can carry the plasmid construct containing the SV40 nuclear 
DTS (SV40-DTS) with them (3-5). Other groups have suc-
cessfully used DTS-containing plasmids. It was reported that 
the direct injection of the modified plasmid into the muscle 
tissue of rats increased gene expression 20-fold (7) and 
10-fold when injected into the blood vessel lumen (8) or 
when electroporated in mouse muscle cells (9).
The efficiency of the SV40-DTS sequence has been 
established by many studies under normoxia, but it has 
never been evaluated under hypoxia. Since the pattern of 
gene expression under hypoxia changes dramatically in 
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response to the new physiological condition (10), the tran-
scription factors used for plasmid transport must also shift. 
Consequently, it is unclear whether the vectors containing 
the SV40-DTS sequence will have the same efficiency of 
transfection under hypoxic condition. In terms of pathology, 
there are many diseases provoked by ischemia such as 
myocardial infarction, critical limb ischemia and stroke. For 
the first two diseases, plasmid-derived vectors have been 
widely used for clinical studies.
Under hypoxia, the hypoxia-inducible factor (HIF) is the 
main activated transcription factor and is responsible for 
the induction of expression of more than 50 genes related 
to hypoxia (11-13). The HIF is a heterodimeric protein with 
two subunits (alpha and beta) constitutively expressed by 
all cells of the body. Under hypoxic conditions, HIF-alpha 
subunits are no longer subjected to proteosomal degradation 
and are thereby able to dimerize with the beta subunits. The 
heterodimeric HIF activates transcription of genes carrying 
hypoxia-responsive elements (HRE), which are present 
in the promoter sequences of those genes (11,12,14). 
Therefore, the HRE sequence is a good candidate for a 
DTS in plasmid vectors constructed for gene therapy of 
ischemic diseases.
The main objective of the present study was to find suit-
able DTS for the construction of plasmid vectors to be used 
to treat ischemic diseases. The well-known SV40-DTS and 
HRE sequences were used to construct plasmid vectors 
and the rate of plasmid nuclear transport and consequent 
gene expression under normoxia (20% O2) and hypoxia 
(less than 5% O2) were determined. Since the human 
vascular endothelial growth factor (hVEGF) gene has been 
extensively used to treat ischemic diseases, this gene was 
used as the reporter gene in our study.
Material and Methods 
Vector construction 
The backbone plasmid constructed for this study was 
named uP. For the uP vector construction, first the 600-bp 
cytomegalovirus (CMV) minimal promoter was removed 
from the pVAX1 vector (Invitrogen, USA) by SpeI enzyme 
digestion (Figure 1). The complete immediate-early human 
CMV promoter from the gWIZ plasmid (Gene Therapy 
Systems, USA) was amplified by PCR with the oligonucle-
otides WIZSE (5’-AAACTAGTACCGCCATGTTGACATTG 
AT-3’) and WIZAS (5’-TTACTAGTCGTGTCAAGGACGG 
TGACTG-3’), both containing 5’ SpeI hydrolysis sites. 
The PCR-amplified products were digested with SpeI and 
inserted into the pVAX1 plasmid, previously digested with 
the same enzyme. The other vectors in this study were 
constructed from the uP backbone.
The SV40-DTS sequence (5’-ATGCTTTGCATACTT 
CTGCCTGCTGGGGAGCCTGGGGACTTTCCACACC 
CTAACTGACACACATTCCACAGCTGGTT-3’ and its com-
plementary sequence) (4,7) and the HRE sequence (5’-GCC 
CTACGTGCTGCCTCGCATGGCCCGGCTGACCTCTTG 
ACCCCTCTGGG-3’ and its complementary sequence) 
(13) were synthesized (Invitrogen, Brazil), phosphorylated 
and annealed. For annealing, each pair of oligonucleotides 
was incubated at 95°C for 5 min in 50 mM NaCl and 1 mM 
EDTA, pH 7.4. After slowly cooling to room temperature, 
the oligonucleotides were purified by precipitation with 0.3 
M sodium acetate. These double-stranded oligonucleotides 
were then inserted into the EcoRV site of the uP vector to 
form the uPS (containing the SV40-DTS) or uPH (contain-
ing the HRE) vectors (Figure 1).
The hVEGF165 gene was cloned by RT-PCR from the 
human lymphoid cell line HL-60 with the oligonucleotides 
VEGFSE (5’-ATTGAATTCCGGGCCTCCGAAACCATG 
AAC-3’) and VEGFAS (5’-TAAGGATCCAGGACTGTTCTG 
TCGATGGTG-3’). The RT-PCR products were phosphory-
lated, digested with EcoRI and ligated into the uP vectors 
that were previously digested with EcoRI and EcoRV (Figure 
1). All new sequences were confirmed by DNA sequencing 
(ABI 3100-Avant, Applied Biosystems, Brazil).
Cell culture, transfection and induction of hypoxia 
in vitro
The human embryonic kidney cell line A293T was 
cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen) supplemented with 2 mM glutamine, 200 µg/mL 
streptomycin, 200 U/mL penicillin and 10% heat-inactivated 
fetal bovine serum (Invitrogen) and maintained at 37°C 
with 5% CO2. Cell hypoxia was induced by the addition 
of cobalt chloride to a final concentration of 100 µM 24 
h before transfection (15,16), and this concentration was 
maintained throughout the experiment. Gene transfer was 
performed via co-precipitation of the uP-derived plasmids 
with calcium phosphate in 35-mm plates containing 2.5 x 105 
cells. Forty-eight hours after transfection, the supernatant 
was collected and used to determine the concentration of 
VEGF by ELISA.
Induction of mouse limb ischemia 
Ten BALB/c mice (12-week-old males) from the animal 
house of the Universidade Federal de São Paulo (UNIFESP) 
were used in the experiments, which were carried out in 
accordance with the recommendations for the proper care 
and use of laboratory animals by the Ethics Committee of 
UNIFESP (approved project No. 842/04). 
Mice were anesthetized with an intraperitoneal injection 
of ketamine and xylazine (40 and 10 mg/kg body weight, 
respectively). To induce limb ischemia, the deep and su-
perficial femoral arteries were excised from their origin as 
a branch of the external iliac artery without damaging the 
femoralis vein or nervus, and were then ligated to the point 
where the femoral artery bifurcates into the saphenous and 
popliteal arteries. These last arteries and the circumflex 
artery were only ligated. Gene transfer was performed by 
injecting 100 μg plasmid in 100 µL PBS in the middle of 
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the thigh with an insulin needle soon after the induction 
of ischemia. After the procedure, the animals were kept 
under analgesia with daily peritoneal injections of 5 mg/
kg carprofen. Forty-eight hours after gene transfer, the 
animals were euthanized by cervical displacement. The 
total mass of the thigh muscle was removed and frozen 
in liquid nitrogen. One milliliter of lysis solution (25 mM 
Tris-HCl, 50 mM NaCl, 0.5% Na-deoxycholate, 2% NP-40, 
0.2% SDS, 1 mM PMSF, 1 µg/mL aprotinin, and 1 µg/mL 
leupeptin) was added per 100 mg tissue, which was then 
homogenized with the Ultra-Turrax T8 homogenizer (Ika, 
USA). The homogenate was centrifuged at 4500 g at 8°C 
for 30 min and the supernatant was used to determine 
protein concentration by the Bradford method (17) and 
VEGF by ELISA.
Determination of VEGF concentration by ELISA
To determine the level of VEGF protein expression by 
ELISA, 96-well plates were incubated with 1 μg/mL rabbit 
polyclonal anti-hVEGF antibody (Peprotech Inc., USA) at 
4°C overnight. After blocking with 3% BSA in PBS at room 
temperature for 1 h, the samples diluted 2-fold in washing 
buffer (0.1% BSA and 0.1% Tween-20 in PBS) were added 
to the 96-well plate and incubated at 4°C for 2 h. After four 
washes with washing buffer, the plates were incubated with 
0.15 µg/mL biotin-conjugated rabbit anti-hVEGF antibody 
for 1 h at 37°C (Peprotech Inc.). Plates were washed four 
times and incubated for 30 min at room temperature with 
1:1000-diluted streptavidin-horseradish peroxidase (Pierce 
Biotech, USA). After thorough washing, the reactions were 
developed by adding 3 mg/mL o-phenylenediamine diluted 
in 50 mM citrate buffer and stopped with 4 N H2SO4. The 
absorbance at 492 nm was measured with an EL 808 Ultra- 
Microplate Reader (Bio-Tek Instruments, Inc., USA). Experi-
ments were carried out at least in triplicate for each sample 
to obtain the mean and standard deviation.
Cell nucleus isolation and quantitative real-time PCR 
For relative quantitation of plasmids using real-time 
quantitative PCR (Q-PCR), the A293T cells were plated and 
transfected as described above. Four hours later, the cells 
were harvested and incubated for 10 min in 10 mM HEPES 
buffer, pH 7.9, containing 10 mM KCl and 1 mM EDTA for 
lysis of the plasma membrane. After isolation of the nuclei 
by centrifugation (15,000 g, 3 min), the QIAMP mini-kit 
(Qiagen, USA) was used for extraction and purification of 
DNA from the nuclei following manufacturer instructions. 
For Q-PCR, the SYBR Green PCR Master Mix (Applied 
Biosystems, Brazil) was used with 0.5 µM of specific primers 
for each gene. Real-time PCR was performed on the ABI 
7700 thermocycler with its software (Applied Biosystems). 
Reactions with primers for the glyceraldehyde 3-phosphate 
dehydrogenase gene (GAPDH) were used to normalize the 
results. The amplification conditions were: 1) one cycle at 
95°C for 10 min, 2) 35 cycles at 94°C for 15 s, 60°C for 30 
s, and 72°C for 30 s. The following primers were used for 
the amplifications: VEGF (5’-TTTCTGCTGTCTTGGGTG 
CATTGG and 5’-ACCACTTCGTGATTCTGCCCT) and 
GAPDH (5’-ACCACAGTCCATGCCATCAC and 5’-TCCA 
CCACCCTGTTGCTGTA). 
For statistical analysis, the results for each experimental 
group were compared independently of the control group. 
Data are reported as means ± SEM (standard error of the 
mean). The unpaired t-test was applied and P < 0.05 was 
considered to be significant in all experiments.
Results and Discussion
To understand the influence of DTS on the transport 
of plasmids to the nucleus under hypoxia and normoxia, 
A293T cells were first transfected with plasmid vectors 
(Figure 1). After 4 h, a sufficient time for a plasmid to enter 
into the nucleus (18), whole nuclear DNA was isolated 
and used for quantitation of the plasmid concentration by 
Q-PCR. In cells transfected with the uPS-hVEGF plasmid, 
the nuclear plasmid concentration under normoxia was 
twice that observed under hypoxia (Figure 2). However, if 
the cells were transfected with the uPH-hVEGF vector this 
situation was reversed, with the concentration of plasmid in 
the nuclei under hypoxia being 2-fold higher than that found 
under normoxia (Figure 2). These statistically significant 
results suggest that the transport of DNA into the nucleus 
depends upon at least two factors: the type of DTS and 
the concentration of oxygen. The profiles of gene expres-
sion under normoxia and hypoxia are different, especially 
with the genes involved in oxygenation. Consequently, the 
DTS used for vector construction should be appropriate for 
each situation. 
The control plasmid uP-hVEGF, which has no known 
DTS but contains the complete CMV intron A sequence, 
presented a statistically significant 30% reduction of nuclear 
plasmid concentration under hypoxia versus normoxia, 
much lower than differences seen with the vectors containing 
DTS (Figure 2). This result indicates that intron A weakly 
facilitates plasmid transport under hypoxia, perhaps through 
the binding of some unknown transcription factor activated 
under hypoxia. These results demonstrate a clear difference 
in the nuclear transport function of the SV40-DTS and HRE 
sequences under hypoxia and normoxia.
The final goal of designing a plasmid vector to treat 
ischemic diseases is to induce a high level of therapeutic 
gene expression under hypoxic condition. Efficient transport 
of the plasmid containing the HRE sequence (uPH-hVEGF) 
under hypoxia does not necessarily indicate that this vector 
will yield a high level of gene expression to produce a high 
concentration of VEGF protein by the transfected cells, be-
cause post-transcription and post-translation modifications 
and protein stability can influence protein determination. 
Therefore, it is fundamental to quantify protein expression 
from those transfected cells.
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In ELISA experiments with the uP-derived vectors under 
normoxia or hypoxia, VEGF gene expression obtained 
by the pVAX-hVEGF plasmid was used for normalization 
since its expression under normoxia or hypoxia did not 
show a significant variation (Figures 3 and 4). This result 
is expected because the expression of VEGF in this vector 
is under the control of only the CMV promoter and without 
no known DTS (19). 
The profiles of VEGF gene expression in vitro for the 
uP-derived vectors were very similar to the nuclear transport 
profiles (Figures 2 and 3); the rate of plasmid transport to 
the nucleus corresponded proportionally to the gene expres-
sion level, with some differences in absolute values. Cells 
transfected with the uPS-hVEGF plasmid produced twice 
the level of VEGF expression under normoxia than under 
hypoxia, while cells transfected with uPH-hVEGF tripled 
VEGF expression under hypoxia compared to normoxia 
(Figure 3). The data from uPS-hVEGF transfection under 
Figure 1. Schematic diagram of the plasmid. An SpeI restriction site was used to replace the CMV minimal 
promoter from pVAX-hVEGF with CMV-A. An EcoRV restriction site was used to insert the S or H sequence in 
the uP-vascular endothelial growth factor 165 (uP-VEGF165) gene vector. S = SV40-DTS (SV40-DNA-targeting 
sequence); H = HRE (hypoxia-responsive element); A = CMV (cytomegalovirus) intron A. 
Figure 2. Q-PCR carried out to determine plasmid concentration 
in the nucleus. A293T cells were transfected with the indicated 
vectors and, after 4 h, the nuclei were isolated and plasmids were 
purified to perform Q-PCR. The Q-PCR results were normalized 
using data from GAPDH amplification. The data are from four 
independent experiments. See Figure 1 for abbreviations. *P < 
0.05 (unpaired t-test).
Figure 3. Vascular endothelial growth factor (VEGF) production 
from cells transfected with the indicated vectors. A293T cells were 
transfected and after 48 h VEGF concentration in the supernatant 
was determined by ELISA. The relative concentration of VEGF is 
reported using the pVAX-hVEGF gene expression under normoxia 
as one. Ten independent experiments were carried out at least in 
triplicate for each point to obtain the mean and standard deviation. 
See Figure 1 for abbreviations. *P < 0.05 (unpaired t-test). 
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normoxia are consistent with previous results (1,4), while 
results from the hypoxia experiments are not in agreement 
with previous results (1,4) and support our hypothesis. The 
presence of the SV40-DTS sequence in the plasmid under 
hypoxia had no additional effect or could decrease gene 
expression (Figure 3), which is not desirable if one intends 
to treat ischemic diseases. In contrast, the high levels of 
gene expression under hypoxia and very low levels under 
normoxia observed with the uPH-hVEGF plasmid are the 
desired results after gene therapy to treat ischemic dis-
eases. The production and action of angiogenic factors are 
required specifically by hypoxic tissues, and those factors 
can provoke pathological angiogenesis, such as tumors, in 
normoxic tissues. Our results from this in vitro study clearly 
demonstrate different levels of gene expression under dif-
ferent oxygen concentrations for plasmids containing the 
SV40-DTS versus HRE sequences. 
In the in vivo study, plasmids were injected into the 
mouse quadriceps and the VEGF concentration was deter-
mined after 48 h. Muscle crude extract rather than blood was 
used for quantification because most VEGF remains at the 
local site of production due to the heparin-binding domain 
of the VEGF molecule (20). Therefore, the concentration 
of VEGF in the blood was very low and sometimes could 
not be detected (data not shown).
The trend of gene expression seen in vitro could be re-
produced in vivo on a much smaller scale, but the variation 
of gene expression was not statistically significant for most 
conditions, even when using about eight animals per group 
(Figure 4). One of the reasons was the high endogenous 
VEGF gene expression caused by the ischemic surgery 
(Figure 4). In addition, variations during in vivo experiments 
are frequently large (7,19,21,22) and probably a larger 
number of animals per group could reduce the standard 
error of the mean, which could be sufficient to demonstrate 
a statistically significant change in gene expression. How-
ever, the gene expression resulting from transfection with 
the uPH-hVEGF plasmid was markedly different from that 
obtained with other vectors and conditions: under ischemic 
conditions it promoted a 10-fold increase in the expres-
sion compared to normoxia (Figure 4). Even compared to 
the uP-hVEGF plasmid under hypoxia, expression from 
the uPH-hVEGF plasmid was 2-fold higher. This result is 
consistent with earlier discussions, which demonstrate that 
the presence of the HRE sequence in the plasmid has a 
stronger effect under hypoxia, a result not observed with 
the vector containing the SV40-DTS (Figure 4). 
The uPH-hVEGF plasmid expressed less than pVAX-
hVEGF under normoxia, opposing the previous result from 
the in vitro study (Figure 3). We have no explanation for 
this, but we suspect that this was caused by one or more 
unknown factors present in skeletal muscle cells that have 
affinity for the DTS present in the uPH-hVEGF plasmid.
Our findings indicate that the inappropriate use of the 
SV40-DTS or HRE sequences in the construction of plasmid 
vectors can strongly affect the expression of heterologous 
genes and compromise the expected therapeutic effect of 
these plasmids. Therefore, vectors should be evaluated 
under physiologically relevant conditions before their ap-
plication to gene therapy.
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